Clinical Trial Update: A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias [Phase 1]

View source ↗

Summary

The trial is a Phase 1 safety and tolerability study of CTX310 in participants with refractory dyslipidemias. It is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Dyslipidemia
• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hypertriglyceridemia
• Metabolic Syndrome

Drugs mentioned

• CTX310

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: Cardiovascular, Metabolic Disease | Phase 1 | Status: RECRUITING